Status:
UNKNOWN
Immunological Markers Predictive of Response and Toxicity to Checkpoint Inhibitors in Non-small Cell Lung Cancer
Lead Sponsor:
University Hospital, Brest
Conditions:
Lung Cancer
Eligibility:
All Genders
18+ years
Brief Summary
A prospective, observational, single-center study to determine the proportion of patients who have or will develop changes in biological markers of immunity during immunotherapy treatment.
Detailed Description
The study will run for 12 months with a 6-month follow-up at the inclusion of the last patient. Patients will be included from the initiation of immunotherapy treatment regardless of the line.The rou...
Eligibility Criteria
Inclusion
- Major patient
- Metastatic non-small cell lung cancer
- Initiation of anti PDL1 therapy (NIVOLUMAB, PEMBROLIZUMAB or ATEZOLIZUAMB) in daily practice
- No objection made
Exclusion
- Autoimmune disease diagnosed prior to initiation of immune checkpoint inhibitor therapy.
- Previous immune-modulating therapy (including corticosteroid therapy greater than 10 mg/day)
- Patient with prior checkpoint inhibitor therapy
- Patient with a contraindication to immunotherapy
- Patient under legal protection
- Refusal to participate
Key Trial Info
Start Date :
April 8 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
October 8 2022
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04918836
Start Date
April 8 2021
End Date
October 8 2022
Last Update
June 9 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU de Brest
Brest, France, 29609